Related Experiment Videos
CypD: The Key to the Death Door
Shaik M Fayaz, Yanamala V Raj, Rajanikant G Krishnamurthy1
1School of Biotechnology, Coordinator, DBT - Centre for Bioinformatics, National Institute of Technology Calicut, Calicut - 673601, India. rajanikant@nitc.ac.in.
CNS & Neurological Disorders Drug Targets
|April 30, 2015
Summary
Cyclophilin D (CypD) regulates the mitochondrial permeability transition pore (MPTP), crucial in neurological diseases. Targeting CypD may offer new treatments for conditions like Alzheimer's and Parkinson's disease.
Area of Science:
- Mitochondrial biology
- Neuroscience
- Cell death mechanisms
Background:
- Cyclophilin D (CypD) is vital in mitochondrial permeability transition pore (MPTP) formation and regulation.
- MPTP dysfunction is implicated in cell death pathways in neurological diseases.
- Abnormal calcium homeostasis and decreased ATP levels are common in these conditions.
Purpose of the Study:
- To review the link between disrupted mitochondrial bioenergetics, calcium dysregulation, and MPTP.
- To explore proteins interacting with CypD and their downstream effects.
- To highlight CypD's central role in cellular demise across neurological disorders.
Main Methods:
- Literature review focusing on CypD, MPTP, calcium homeostasis, and mitochondrial bioenergetics.
- Analysis of protein-CypD interactions and their pathological consequences.
- Synthesis of information on cell death pathways converging at CypD.
Main Results:
- CypD mediates persistent MPTP opening, leading to cell death, often triggered by elevated calcium levels.
- Mitochondrial bioenergetic disruption is connected to abnormal calcium handling and MPTP activity.
- CypD acts as a convergence point for cell death pathways in various neurological disorders.
Conclusions:
- CypD is a key regulator of cell death in neurological diseases.
- Inhibitors of CypD show therapeutic potential for Alzheimer's disease, Parkinson's disease, and cerebral ischemia.
- Understanding CypD's role in MPTP and cell death is crucial for developing new disease treatments.